DURHAM, N.C. and BEIJING, June 25, 2023 /PRNewswire/-- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve ...
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri ® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated ...
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage ...
English Session: August 21 at 9:00 p.m. HKT / 9:00 a.m. ET Chinese Session: August 22 at 9:00 a.m. HKT / August 21 at 9:00 p.m. ET In the first half of 2025, Brii Bio rapidly advanced its core ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results